Published • loading... • Updated
Accro Bioscience Announces Inclusion of AC-101 tablets in the NMPA CDE's "Caring Plan-Extension" Pilot Program for Rare Disease Drug Development
- Accro Bioscience announced on September 14, 2026, that AC-101 tablets were included in China's NMPA CDE Rare Diseases Innovative Drug Development Encouragement Pilot Program for Blau syndrome.
- The U.S. FDA granted AC-101 Rare Pediatric Disease designation for treating Blau syndrome in June 2026.
- AC-101 is a novel RIPK2 inhibitor developed by Accro Bioscience to target regulatory cell death and inflammation.
- AC-101 completed Phase I safety and pharmacokinetic studies in healthy volunteers in Australia and China.
Insights by Ground AI
40 Articles
40 Articles
Accro Bioscience Announces Inclusion of AC-101 tablets in the NMPA CDE's "Caring Plan-Extension" Pilot Program for Rare Disease Drug Development
NEW YORK and SUZHOU, China, Sept. 13, 2026 /PRNewswire/ -- On September 14, 2026 (China Standard Time, UTC+8), Accro Bioscience announced that AC-101 tablets have been included in the Rare Diseases Innovative Drug Development Encouragement Pilot Program (the "Caring Plan-Extension",…
·Pennsylvania, United States
Read Full ArticleCoverage Details
Total News Sources40
Leaning Left5Leaning Right5Center22Last UpdatedBias Distribution69% Center
Bias Distribution
- 69% of the sources are Center
69% Center
L 16%
C 69%
15%
Factuality
To view factuality data please Upgrade to Premium
